Meda, Medivir to develop, commercialize cold-sore drug
STOCKHOLM, Sweden Meda plans to work with Medivir to commercialize a cold-sore drug in North America, the Swedish drug maker announced.
Meda and Medivir plan to market the drug Xerese (lipsovir) in the United States, Canada and Mexico as a treatment for cold sores, also known as herpes labialis. The drug, a combination of acyclovir and hydrocortisone, received approval from the Food and Drug Administration in July 2009.
Under the deal, Meda will fund commercial development of the drug and pay Medivir $5 million in up-front and pre-launch milestones, as well as double-digit royalties on sales.
“Xerese is a very interesting addition to our product portfolio in the U.S.,” Meda CEO Anders Lonner said in a statement. “It’s already registered and has a unique and differentiating claim. When commercial stock is in place, we will launch it.”
Duane Reade opens fifth walk-in medical clinic in New York
NEW YORK A new walk-in clinic at a Duane Reade store in Chelsea officially opened on Wednesday, making it the fifth Duane Reade location with “Doctor on Premises” walk-in medical care.
The physician-staffed clinic is managed by Consumer Health Services and is also affiliated with Beth Israel Medical Center and St. Luke’s-Roosevelt Hospital Center. It is open Monday through Saturday, 10 a.m. to 6 p.m., and accepts most insurance plans.
“Walk-in, neighborhood-based medical care is a growing trend in this country, and it’s a very positive trend,” stated Dr. Maggie Bertisch, M.D., medical director for New York Walk-In Medical Group PC. “It allows healthcare providers to offer a more convenient, affordable alternative to crowded emergency rooms, while delivering safe, quality medical care in a New York minute.” According to CHS, Duane Reade is planning to add more on-site health clinics in 2010.
As reported, Walgreens, which owns retail-based clinic operator Take Care Health Systems, announced on Wednesday that is has reached an agreement to buy Duane Reade in a deal valued at nearly $1.1 billion.
Hi-Tech Pharmacal, Mission Pharmacal to market new kidney stone treatment
AMITYVILLE, N.Y. Hi-Tech Pharmacal and Mission Pharmacal Co. are planning to market a new treatment for kidney stones to doctors starting in April, the drug maker announced Wednesday.
Under a license agreement between the two companies, Hi-Tech will promote UroCit-K 15mEq (potassium citrate) extended-release tablets to primary care physicians through subsidiary ECR Pharmaceuticals, while Mission will promote it to urologists. The drug is a twice-daily treatment.
“We are pleased to introduce another unique prescription branded product to the primary care market,” Hi-Tech president and CEO David Seltzer said in a statement. “UroCit-K 15mEq is a highly effective product, available in a convenient dosing regimen which will increase patient compliance.”